Hemophilia A

An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A

NCT02172950 | PHASE 3 | INTERVENTIONAL

This multicenter, open-label, phase 3 extension study will investigate the safety and efficacy of rVIII-SingleChain for prophylaxis and on-demand treatment of bleeding episodes in at least 200 previously treated patients (PTPs) with severe congenital hemophilia A and previous exposure to FVIII products who achieve at least 100 exposure days (EDs) to rVIII-SingleChain in this study, as well as in previously untreated patients (PUPs) with no previous exposure to any FVIII product who achieve at least 50 EDs to rVIII-SingleChain in this study. A substudy (open to both PTPs and PUPs) will investigate the use of rVIII-SingleChain in surgery. A substudy (open to PUPs who develop an inhibitor to rVIII-SingleChain) will investigate the use of rVIII-SingleChain in immune tolerance induction (ITI) therapy.

64 Sites

246 Participants

Recruiting

18 Years to 55 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Find closest sites:

SUBMIT

Study Site

San Diego,California,United States,92103

Study Site

Aurora,Colorado,United States,80045

Study Site

Hartford,Connecticut,United States,06106

Study Site

Miami,Florida,United States,33136

Study Site

Chicago,Illinois,United States,60612

Study Site

New Orleans,Louisiana,United States,70112

Study Site

Dallas,Texas,United States,75390

Study Site

Houston,Texas,United States,77030

Study Site

Milwaukee,Wisconsin,United States,53226

Study Site

Melbourne,Australia,3052

Study Site

Nedlands,Australia,WA6009

Study Site

Perth,Australia,WA6000

Study Site

Graz,Austria,8036

Study Site

Linz,Austria,4020

Study Site

Wien,Austria,1090

Study Site

Wien,Austria,1090

Study Site

Saint John,Canada,E2L4L2

Study Site

Hradec Kralove,Czechia,50005

Study Site

Brest,France,29609

Study Site

Le Kremlin Bicetre,France,94270

Study Site

Lille Cedex,France,59037

Study Site

Nantes,France,44093

Study Site

Paris,France,75015

Study Site

Tbilisi,Georgia,0179

Study Site

Bonn,Germany,53127

Study Site

Frankfurt,Germany,60596

Study Site

Giessen,Germany,35385

Study Site

Hannover,Germany,30625

Study Site

Debrecen,Hungary,4032

Study Site

Dublin,Ireland,12

Study Site

Milano,Italy,20122

Study Site

Hyogo,Japan,663-8501

Study Site

Nagoya,Japan,466-8550

Study Site

Okayama,Japan,710-8602

Study Site

Saitama,Japan,339-8551

Study Site

Tokyo,Japan,160-0023

Study Site

Beirut,Lebanon,165191

Study Site

Kuala Lumpur,Malaysia,50400

Study Site

Amsterdam Zuidoost,Netherlands,1105AZ

Study Site

Nijmegen,Netherlands,6500

Study Site

Utrecht,Netherlands,3584

Study Site

Cebu City,Philippines,6000

Study Site

Davao City,Philippines,8000

Study Site

Gdansk,Poland,80-952

Study Site

Krakow,Poland,31-531

Study Site

Rzeszow,Poland,35-301

Study Site

Wroclaw,Poland,50-367

Study Site

Porto,Portugal,4200-319

Study Site

Bucharest,Romania,011026

Study Site

Timisoara,Romania,300011

Study Site

Parktown,South Africa,2193

Study Site

A Coruna,Spain,15006

Study Site

Barcelona,Spain,08035

Study Site

Madrid,Spain,28046

Study Site

Valencia,Spain,46026

Study Site

Luzern,Switzerland,6000

Study Site

Bangkok,Thailand,10330

Study Site

Bangkok,Thailand,10700

Study Site

Chiang Mai,Thailand,50200

Study Site

Khon Kaen,Thailand,40002

Study Site

Songkhla,Thailand,90110

Study Site

Dnipropetrovsk,Ukraine,49102

Study Site

Lviv,Ukraine,79044

Study Site

London,United Kingdom,NW32QG

Study Eligibility Criteria

Inclusion Criteria

PTPs:
* Males of any age who have been diagnosed with severe congenital hemophilia A (FVIII activity levels \< 1%) and who participated in a previous CSL-sponsored clinical study with rVIII-SingleChain.
* Males 0 to \<65 years age who have been diagnosed with severe congenital hemophilia A (FVIII activity levels \< 1%), who have at least 50 EDs to any FVIII product, and who are not currently enrolled in a CSL-sponsored clinical study with rVIII-SingleChain.
PUPs:
* Males 0 to \<18 years of who have been diagnosed with severe congenital hemophilia A (FVIII activity levels \< 1%)
* No prior exposure to any Factor VIII product (with the exception of short-term use of blood products).
ITI substudy:
* PUPs who have developed a confirmed inhibitor to rVIII-SingleChain in the main study.

Exclusion Criteria

* Known or suspected hypersensitivity to rVIII-SingleChain or to any excipients of rVIII-SingleChain or Chinese hamster ovary (CHO) proteins.
* Currently receiving a therapy not permitted during the study.
* Serum creatinine \> 2 x upper limit of normal, alanine aminotransferase or aspartate aminotransferase \> 5 x upper limit of normal at Screening (if specified)
* Any first-order family (eg, siblings) history of FVIII inhibitors
* For PTPs not rolling over directly from a CSL-sponsored clinical study with rVIII-SingleChain: any history of or current FVIII inhibitors

Additional Studies

Additional studies can be found at ClinicalTrials.gov